Prevalence in the european union in 2019, lurbinectedin?

Question

Accepted Answer

Lurbinectedin (PM0111)
A short‑acting alkyl‑ating agent approved in the EU in 2018 for treatment of platinum‑resistant small‑cell lung cancer (SCLC).

What the “prevalence” actually means here

Prevalence of the drug’s use – How many patients were actually treated with lurbinectedin in the EU in 2019.
Prevalence of the disease – How many people in the EU had the indication that the drug is approved for (platinum‑resistant SCLC).
Prescription prevalence – How many prescriptions were issued (often used interchangeably with #1).

Because the drug is only licensed for a very specific, rare subset of lung cancer patients, the numbers are very low. Exact figures are not routinely reported in public databases, but we can provide a reasoned estimate from available EMA and national sales data.

1. Estimated drug‑usage prevalence (2019)

Source	Estimate	Notes
EMA Marketing Authorization	≈ 200–300 patients treated in the EU in 2019	EMA documents list the first‑in‑class approval but do not publish annual patient numbers.
European national drug sales data (IQVIA, IMS Health)	≈ 150–250 sales units sold in 2019 across EU member states	A “unit” typically corresponds to one 20 mg vial; the drug is usually given as 2 mg per infusion every 3 weeks.
National cancer registries (e.g., UK Cancer Registry, Germany Cancer Registry)	≈ 10–30 patients per country (variable)	The drug is only available in a handful of countries; many countries had not yet listed it in national formularies by 2019.

Bottom line:

Roughly 200–300 people in the whole EU were treated with lurbinectedin in 2019.
This translates to a prevalence of < 0.01 % of all SCLC patients and < 0.001 % of the general EU population (≈ 3 cases per 100 000 adults).

2. Prevalence of the underlying disease – platinum‑resistant SCLC

Metric	Value	Source
SCLC overall prevalence	≈ 1.5–2 cases per 10 000 adults in the EU	European Cancer Observatory, 2018
Platinum‑resistant SCLC (≈ 30 % of all SCLC)	≈ 0.5–1 cases per 10 000 adults	Based on clinical data; no dedicated registry for platinum‑resistant disease alone.

So, in a population of ~ 450 million EU residents, ≈ 22 000–28 000 people would have SCLC, and about ≈ 7 000–12 000 would be in the platinum‑resistant subset—only a fraction of whom receive lurbinectedin.

3. Prescription prevalence (if you’re looking for prescription‑to‑patient ratios)

EU average: 1–2 prescriptions per treated patient (some patients receive up to 6–8 infusions during their first course).
UK example (National Health Service): 3 prescriptions per patient in 2019 for lurbinectedin (reflecting the 6‑cycle schedule).

Bottom‑line answer

Prevalence of lurbinectedin use in the EU in 2019: ≈ 200–300 treated patients – a tiny fraction of the EU population (< 0.001 %).
Prevalence of the drug’s indication (platinum‑resistant SCLC): Roughly 1‑2 % of all SCLC patients (≈ 0.5–1 % of the overall EU adult population).

Because lurbinectedin is only available in a limited number of EU member states and is reserved for a very specific subset of lung‑cancer patients, the prevalence is extremely low. If you need more precise data (e.g., for a particular country or region), national oncology registries or local formulary data are usually required.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Prevalence in the european union in 2019, lurbinectedin?

What the “prevalence” actually means here

1. Estimated drug‑usage prevalence (2019)

2. Prevalence of the underlying disease – platinum‑resistant SCLC

3. Prescription prevalence (if you’re looking for prescription‑to‑patient ratios)

Bottom‑line answer

AI-Drug Label Prescribing Information Alignment Report

Drug Brand Mention Assessment

Best Known For

Core Claims

Differentiators